PhRMAG Forum 2017

Enhancing Knowledge-Based Economy to Advance Human Health

The PhRMAG Executive Committee is proud to conduct its first annual conference in the Gulf Cooperation Council (GCC) region on 7th December 2017. This first annual conference, PhRMAG Forum 2017, will be under the patronage of HH Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance and President of the Dubai Health Authority. It will bring together the private and public sector stakeholders to examine topical issues concerning patients, healthcare providers and the innovative biopharmaceutical sector.

Date : 7th of December 2017
Venue : Shagri-La Hotel, Dubai, UAE
Topics Addressed :

  • Value of Innovative Biopharmaceutical Sector
  • Value of Innovative Medicines
  • Value of PhRMAG as a Partner to Stakeholders in the Gulf Healthcare Arena

FACULTY

Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.  Mr. Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress.

David Torstensson is a partner with Pugatch Consilium. David’s focus is in policy and economic analysis related to innovation, intellectual property, tax, health care and pharmaceuticals. He is the author of a number of commissioned research papers and academic publications. David has wide experience in quantitative research methods including index-building and data sampling. Most recently David designed and co-authored the 2017 International IP Index for the U.S. Chamber of Commerce and the 2017 Biopharmaceutical Competitiveness Index Survey commissioned by PhRMA. His knowledge spans from North America and Europe to the BRIC economies, the Middle East and Latin America. Prior to his work with Pugatch Consilium, David was with Deloitte LLP. David holds a Master of Studies and DPhil (PhD) from Oxford University.

Peter Pitts is President of the Center for Medicine in the Public Interest. A former member of the United States Senior Executive Service, Peter was FDA’s Associate Commissioner for External Relations, serving as senior policy adviser to the Commissioner. He supervised FDA’s Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. In 2010 he was named by Modern Healthcare magazine as one of the 300 “most powerful people in American healthcare.” He is a Visiting Lecturer at the École Supérieure des Sciences Économiques et Commerciales (Paris and Singapore).

AGENDA

8.30-9.00 Registration | Badge Collection
9.00 – 9.15 HE Humaid Mohammad Obaid Al Qutami Director-General of the DHA – Opening Remarks
9.15 -9.30 Ministry of Health & Prevention – Opening Remarks | TBC
9.30 – 9.45 Dr. Yacoub Haddad – Keynote
 
9.45-10.45 Theme I: Value of Innovative Biopharmaceutical Sector
The innovative biopharmaceutical industry invests in R&D and capital improvements.

What are the opportunities for the Gulf Countries in this strategic, dynamic sector?

9.45 – 10.00 HE Dr. Amin Hussein Al Amiri
Assistant Undersecretary for Public Health Policy and Licensing Sector, MOHP
10.00 -10.15 Dhiraj Joshi – PWC Partner Footprint Report
10.15 – 10.30 David Torstensson – Biopharmaceutical Competitiveness Report
 10.30 – 10.45 Dr. Mohammed Baniyas – Knowledge Based Economy, UAE Perspective
 10.45 – 11.00 Panel Discussion with Q&A:
Untapped potential and what can Industry Partnership bring to the table?
Yacoub Haddad + David Torstensson + Dr. Mohammed Baniyas + Dhiraj Joshi + HE Dr. Amin Hussein Al Amiri
11.00 – 11.15 Break
11.00 – 12.00 Theme II: Value of Innovative Medicines
The impact of innovative medicines and vaccines on patients and the healthcare system
11.00-11.20 Frank Lichtenberg The impact of new drug launches on longevity in 9 Middle Eastern & African Countries, 2007 – 2015
11.20-12.00 Panel Discussion with Q&A :
Opportunities in the Gulf Countries and Future Plans
         Samir Khalil + Frank Lichtenberg +   Dr. Ramadan Al Blooshi   + Dr. Ali Al Sayed
12.00-1.00 Theme III: Value of PhRMAG as a Partner to Stakeholders in the Gulf Healthcare Arena
How countries are drawing the most value out of innovative medicines and attracting more investment and employment from this innovative, high value-added sector.
12.00-12.20 Peter Pitts – Partnerships from Global Perspective
12.20-1.00 Panel Discussion with Q&A:
Future Partnerships – PPP
Dream Samir + Peter Pitts + Laura Nassar + Butti Ahmad Bin Darwish Al Falasi + Marwan Abdulaziz Janahi      
1.00-2.00 Networking Lunch
2.00-2.45 INNOVATION Workshops
Led by – Dubai Science Park
Q&A
Closing remarks